Orchard Therapeutics PLC
Andrew Olaye has extensive experience in market access and partnerships in the pharmaceutical industry. Andrew has held senior roles at companies such as Orchard Therapeutics, BioMarin Pharmaceutical Inc., Vertex Pharmaceuticals, Grünenthal Group, and LA-SER EUROPE. Their work has focused on health economics, market access, and reimbursement strategies within the European market.
Andrew Olaye holds an MSc in Health Economics, Policy and Management from The London School of Economics and Political Science (LSE). Andrew also earned an MPharm in Pharmacy from The School of Pharmacy, University of London, and a PhD in Pharmacy with a focus on Tissue Engineering / Regenerative Medicine from the University of Nottingham.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.